Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Thermo Scientific™ QMS™ Therapeutic Drug Monitoring (TDM) Assays
Click to view available options
Quantity:
1 x 14 mL, 1 x 12 mL
1 x 19 mL, 1 x 14 mL
1 x 19 mL, 1 x 7 mL
1 x 19 mL, 1 x 8 mL
2 x 19 mL
2 x 19 mL, 2 x 7 mL
2 x 19 mL, 2 x 8 mL
2 x 22 mL, 2 x 8 mL
22 x 16 mL
Detectable Analytes:
Amikacin
Gentamicin
Lamotrigine
Quinidine
Tobramycin
Topiramate
Vancomycin
Zonisamide
Description
Accurately measure therapeutic drug levels in serum and plasma with the Thermo Scientific™ QMS™ Therapeutic Drug Monitoring (TDM) Assays. These liquid, ready-to-use assays are a convenient alternative to more expensive and time-consuming technologies. QMS (Quantitative Microsphere System) immunoassays have excellent precision and accuracy, optimized performance on a wide range of general chemistry analyzers and lot-to-lot consistency.
Reduces Labor
- Significantly reduces labor, time, and expense compared to HPLC or LCMS and other technologies
- Based on competitive inhibition immunoassay principle whereby free-drug in the sample competes for antibody binding sites with drug molecules coated onto uniform microparticles
- Liquid stable and ready-to-use
- Applicable to general chemistry analyzers
- Validated parameters assure lab-to-lab reproducibility
- Superb reagent stability
- Excellent correlation to reference methods
- Optimal sensitivity, precision and dynamic range
- Low cross-reactivity with metabolites and commonly co-administered drugs
- Low interference from endogenous substances

Specifications
Specifications
Content And Storage | 2°C to 8°C |
Description | Zonisamide Assay for Indiko |
Detectable Analytes | Zonisamide |
Sample Type | Plasma, Serum |
Type | Reagent |
Quantity | 2 x 19 mL, 2 x 8 mL |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction